Foghorn Therapeutics Inc. Operating Income
Foghorn Therapeutics Inc. (FHTX) reported Operating Income of -$8.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Foghorn Therapeutics Inc. operating income (loss) for the quarter ending 2026-06-30 was -$8.80M.
- Foghorn Therapeutics Inc. operating income (loss) for the quarter ending 2026-03-31 was -$21.57M.
- Foghorn Therapeutics Inc. operating income (loss) for the quarter ending 2025-12-31 was -$23.88M.
- Foghorn Therapeutics Inc. operating income (loss) for the quarter ending 2025-09-30 was -$18.50M.
- Foghorn Therapeutics Inc. operating income (loss) for fiscal 2025 was -$86.39M.
- Foghorn Therapeutics Inc. operating income (loss) for fiscal 2024 was -$102.68M.
- Foghorn Therapeutics Inc. operating income (loss) for fiscal 2023 was -$107.91M.
- Foghorn Therapeutics Inc. operating income (loss) for fiscal 2022 was -$117.14M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.80M 10-Q · filed 2026-08-06 | -$30.38M 10-Q · filed 2026-08-06 | -$54.26M derived: sum of 3 quarters · filed 2026-08-06 | -$72.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$21.57M 10-Q · filed 2026-05-07 | -$45.45M derived: sum of 2 quarters · filed 2026-05-07 | -$63.95M derived: sum of 3 quarters · filed 2026-05-07 | -$85.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$23.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$42.38M derived: sum of 2 quarters · filed 2026-03-11 | -$63.48M derived: sum of 3 quarters · filed 2026-08-06 | -$86.39M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$18.50M 10-Q · filed 2025-11-05 | -$39.60M derived: sum of 2 quarters · filed 2026-08-06 | -$62.51M 10-Q · filed 2025-11-05 | -$86.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$21.10M 10-Q · filed 2026-08-06 | -$44.01M 10-Q · filed 2026-08-06 | -$68.02M derived: sum of 3 quarters · filed 2026-08-06 | -$91.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$22.91M 10-Q · filed 2026-05-07 | -$46.92M derived: sum of 2 quarters · filed 2026-05-07 | -$70.77M derived: sum of 3 quarters · filed 2026-05-07 | -$97.40M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$47.86M derived: sum of 2 quarters · filed 2026-03-11 | -$74.49M derived: sum of 3 quarters · filed 2026-03-11 | -$102.68M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$23.85M 10-Q · filed 2025-11-05 | -$50.48M derived: sum of 2 quarters · filed 2025-11-05 | -$78.68M 10-Q · filed 2025-11-05 | -$104.14M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$26.63M 10-Q · filed 2025-08-05 | -$54.83M 10-Q · filed 2025-08-05 | -$80.28M derived: sum of 3 quarters · filed 2025-08-05 | -$97.36M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$28.19M 10-Q · filed 2025-05-14 | -$53.65M derived: sum of 2 quarters · filed 2025-05-14 | -$70.73M derived: sum of 3 quarters · filed 2025-05-14 | -$102.78M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$25.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$42.54M derived: sum of 2 quarters · filed 2025-03-06 | -$74.59M derived: sum of 3 quarters · filed 2025-03-06 | -$107.91M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$17.08M 10-Q · filed 2024-11-04 | -$49.13M derived: sum of 2 quarters · filed 2024-11-04 | -$82.45M 10-Q · filed 2024-11-04 | -$114.33M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | -$32.05M 10-Q · filed 2024-08-08 | -$65.37M 10-Q · filed 2024-08-08 | -$97.25M derived: sum of 3 quarters · filed 2024-08-08 | -$125.51M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$33.32M 10-Q · filed 2024-05-06 | -$65.20M derived: sum of 2 quarters · filed 2024-05-06 | -$93.46M derived: sum of 3 quarters · filed 2024-05-06 | -$122.65M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$31.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$60.15M derived: sum of 2 quarters · filed 2024-03-07 | -$89.33M derived: sum of 3 quarters · filed 2024-03-07 | -$117.14M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$28.26M 10-Q · filed 2023-11-02 | -$57.45M derived: sum of 2 quarters · filed 2023-11-02 | -$85.25M 10-Q · filed 2023-11-02 | -$113.33M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$29.19M 10-Q · filed 2023-08-04 | -$56.99M 10-Q · filed 2023-08-04 | -$85.07M derived: sum of 3 quarters · filed 2023-08-04 | -$111.33M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | -$27.80M 10-Q · filed 2023-05-08 | -$55.89M derived: sum of 2 quarters · filed 2023-05-08 | -$82.15M derived: sum of 3 quarters · filed 2023-05-08 | -$105.41M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$28.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$54.34M derived: sum of 2 quarters · filed 2023-03-09 | -$77.60M derived: sum of 3 quarters · filed 2023-03-09 | -$100.73M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$26.26M 10-Q · filed 2022-11-08 | -$49.52M derived: sum of 2 quarters · filed 2022-11-08 | -$72.65M 10-Q · filed 2022-11-08 | -$93.43M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$23.26M 10-Q · filed 2022-08-09 | -$46.39M 10-Q · filed 2022-08-09 | -$67.17M derived: sum of 3 quarters · filed 2022-08-09 | -$85.66M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$23.13M 10-Q · filed 2022-05-09 | -$43.91M derived: sum of 2 quarters · filed 2022-08-09 | -$62.40M derived: sum of 3 quarters · filed 2022-08-09 | -$77.94M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | -$20.78M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | -$39.27M derived: sum of 2 quarters · filed 2022-08-09 | -$54.81M derived: sum of 3 quarters · filed 2022-08-09 | -$68.53M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | -$18.49M 10-Q · filed 2021-11-09 | -$34.03M derived: sum of 2 quarters · filed 2021-11-09 | -$47.75M 10-Q · filed 2021-11-09 | -$62.94M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$15.54M 10-Q · filed 2021-08-10 | -$29.26M 10-Q · filed 2021-08-10 | -$44.45M derived: sum of 3 quarters · filed 2021-08-10 | -$57.55M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$13.72M 10-Q · filed 2021-05-11 | -$28.91M derived: sum of 2 quarters · filed 2021-05-11 | -$42.01M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$15.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$28.29M derived: sum of 2 quarters · filed 2021-03-18 | -$51.08M 10-K · filed 2021-03-18 | |
| 2019-09-30 | -$13.10M 10-Q · filed 2020-12-04 | -$35.90M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |